Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
DBV Technologies SA (DBVT) is a clinical-stage biopharmaceutical leader advancing epicutaneous immunotherapy (EPIT) through its innovative Viaskin platform, targeting food allergies with non-invasive precision. This page aggregates all essential updates on the company’s clinical progress, regulatory milestones, and strategic initiatives.
Investors and stakeholders gain centralized access to critical developments including phase trial results, FDA/EMA interactions, and partnership announcements. Each update is curated to provide actionable insights into DBVT’s pioneering work in allergy treatment while maintaining rigorous scientific accuracy.
Key coverage areas include Viaskin efficacy data, patent developments, and manufacturing scalability updates. The resource is designed to help users track the company’s progress from clinical research to potential commercialization without requiring cross-platform monitoring.
Bookmark this page for streamlined tracking of DBV Technologies’ advancements in redefining food allergy management through its unique skin-based immunotherapy approach.
DBV Technologies (NASDAQ: DBVT) announced the immediate resignation of Daniel Soland from its Board of Directors. Soland, who joined the board in 2015, served on the Compensation Committee and contributed his expertise to the company's development of the VIASKIN® Peanut patch for peanut allergic children.
The Board will continue to operate with 9 remaining members while the Nomination and Governance Committee evaluates the timing and process for appointing a new member, subject to shareholder ratification at the next Annual General Meeting.
DBV Technologies (NASDAQ:DBVT) has established a new At-The-Market (ATM) Program on Nasdaq, allowing the company to sell up to $150 million of American Depositary Shares (ADS). Each ADS represents five ordinary shares, with Citizens JMP Securities acting as sales agent.
The proceeds will primarily fund activities related to the Biologics License Application (BLA) and potential launch of VIASKIN® Peanut patch for toddlers aged 1-3 years, along with advancing their VIASKIN platform development. The program could result in a maximum potential dilution of approximately 50% based on existing share capital, with sales limited to qualified investors in the pharmaceutical and biotechnology sectors.
DBV Technologies (NASDAQ:DBVT), a clinical-stage biopharmaceutical company, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CEO Daniel Tassé will engage in a fireside chat on September 9, 2025, at 11:30am ET in New York.
The presentation will be accessible through a live webcast and will remain available for replay on the company's investor relations website for 90 days after the event.
DBV Technologies (NYSE:DBVT) has reported its monthly update on voting rights and share count as of July 31, 2025. The company disclosed a total of 136,975,159 shares outstanding, with the same number of gross voting rights. The net total of voting rights stands at 136,810,568, reflecting shares without voting rights.
This disclosure is made in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers for companies listed on NYSE Euronext Paris.
DBV Technologies (NASDAQ:DBVT), a clinical-stage biopharmaceutical company specializing in food allergies and immunologic treatments, has announced the filing of its 2025 Half-Year Report with the French market authority (AMF) for the period ending June 30, 2025.
The report is available in French on the company's website under the Investors/Financial Information section, on the AMF website, and can be requested directly from DBV Technologies via mail or email.
DBV Technologies (NASDAQ:DBVT) reported its Q2 and H1 2025 financial results, highlighting a challenging period with increased operating expenses and net losses. The company's operating expenses rose to $69.9 million for H1 2025, up from $65.0 million in H1 2024, primarily due to the COMFORT Toddlers safety study launch.
Net loss increased to $69.0 million in H1 2025 from $60.5 million in H1 2024, with loss per share at $(0.58). Cash position strengthened to $103.2 million as of June 30, 2025, boosted by a March financing deal of up to $306.9 million, including $125.5 million received in April. The company expects current cash to fund operations into Q2 2026, though substantial going concern doubts remain.
DBV Technologies (NASDAQ: DBVT) has released its half-year report regarding its liquidity contract with ODDO BHF. As of June 30, 2025, the liquidity account held 210,069 DBV Technologies shares and €171,301.08 in cash.
During H1 2025, the company executed 2,204 buy transactions and 2,398 sales transactions, with trading volumes of 1.16 million shares (€1.49M) purchased and 1.21 million shares (€1.56M) sold. This represents the activity since the contract's implementation on July 1, 2018, when the account started with 41,159 shares and €432,367.25.
DBV Technologies (NASDAQ: DBVT), a clinical-stage biopharmaceutical company, has appointed James Briggs as its new Chief Human Resources Officer, replacing Caroline Daniere. This strategic appointment comes as DBV prepares for its transition from a development-stage biotech to a potential commercial organization.
Briggs, who will report to CEO Daniel Tassé and join the Executive Committee, brings significant experience as a former Partner at East Bay Human Capital and CEO of MNG Health. He previously served as CHRO at several organizations including Ciox Health and Ikaria Inc. Briggs holds a Master's in Human Relations, is SPHR certified, and has a Six Sigma Green Belt certification.
DBV Technologies (NASDAQ:DBVT) has announced the screening of its first subject in the COMFORT Toddlers supplemental safety study for their Viaskin® Peanut patch 250 μg, targeting peanut-allergic children ages 1-3 years old.
The Phase 3 double-blind, placebo-controlled study will enroll approximately 480 subjects across 80-90 study centers in the U.S., Canada, Australia, UK, and Europe. The study includes a 6-month initial phase followed by an optional 18-month open-label treatment phase. The first screening took place at the Respiratory Medicine Research Institute of Michigan, with additional sites in Minnesota and Ontario now activated.
The data from this study will support a Biologics License Application (BLA) submission anticipated in 2H 2026 under the Accelerated Approval Pathway, complementing the previously completed Phase 3 EPITOPE study data.
FAQ
What is the current stock price of Dbv Technologies S A (DBVT)?
What is the market cap of Dbv Technologies S A (DBVT)?
